ClinicalTrials.gg
Drug

Pumitamig clinical trials

Also written PM8002 and BNT327.

studies test it
36
open now
25
in phase 3
9
first study started
2021

How each study uses pumitamig is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the pumitamig studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Pumitamig
20
BNT327 Dose Level 1 (DL1)
2

Development codes

PM8002
26
BNT327
18
BMS-986545
14

Studies by the year they started

36 studies that test it; most in 2025 (13)

Studies that test pumitamig, by start year
YearStudies
20211
20224
20233
20245
202513
202610

By phase

A phase 1/2 study counts in both.

Phase 1
13
Phase 2
30
Phase 3
9

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 34 · Other 2

BioNTech SE (12) · Biotheus Inc. (11) · Bristol-Myers Squibb (9) · Shanghai Pulmonary Hospital, Shanghai, China (1) · Boehringer Ingelheim (1) · DualityBio Inc. (1) · M.D. Anderson Cancer Center (1)

Often tested with

Tested in the same studies.

Paclitaxel (2) · Beruzatatug pelitecan (2) · Etoposide (1) · Carboplatin (1) · Topotecan (1) · Anti-TIGIT/Anti-PVRIG Bispecific Antibody PM1009 (1) · Trastuzumab pamirtecan (1) · Obrixtamig (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4, 2 in phase 3

Studies that test pumitamig, phase 3 first.

Studies

Open first, then newest update. How each study uses pumitamig is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 36

See all 36 studies that test pumitamig →

Given beside what is tested · 10 — pumitamig is usual care or a partner of the new treatment

Codes

What other systems call pumitamig · ClinicalTrials.gg INT017680

  • UNII (FDA) QEA2EG9S3EPUMITAMIGOne source FDA
  • NCI Thesaurus C215265PumitamigOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.